DNA News and Research

RSS

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Good Start Genetics $18 million Series A financing round co-led by Safeguard Scientifics

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that it has co-led a $18 million Series A financing round for Good Start Genetics, Inc. with OrbiMed Advisors, LLC and SV Life Sciences Advisers LLP.

10 Sep 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2010 fiscal year ended June 30, 2010.

10 Sep 2010

SAEC collaborates with Newcastle University for drug induced liver injury research

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with Newcastle University to research the genetics of drug induced liver injury.

10 Sep 2010

Research into role of genetic variation in drug-induced hypersensitivity reactions

The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool (www.liv.ac.uk/pharmacogenetics) to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the body's immune system, and mostly involve serious skin rashes.

10 Sep 2010

Researchers discover mechanism that prevents stem cell from becoming another cell type

Johns Hopkins researchers have determined why certain stem cells are able to stay stem cells.The report in the June 4 issue of Cell Stem Cell reveals that an enzyme that changes the way DNA is packaged in cells allows specific genes to be turned on and off, thereby preventing a stem cell from becoming another cell type.

10 Sep 2010

Kennedy Krieger Institute receives grant for Alzheimer's disease research in Down syndrome patients

Early signs of Alzheimer's disease can be difficult to distinguish from the normal aging process in any older adult. For adults with Down syndrome, who are particularly vulnerable to Alzheimer's disease, it is even more so. Because effective intervention needs to begin as early in the disease process as possible, prior to the onset of the irreversible impacts on the brain that are characteristic of this devastating disease, early diagnosis is of critical importance. To address crucial gaps in knowledge about Alzheimer's disease in adults with Down syndrome, the Kennedy Krieger Institute has been awarded an $8.5 million grant from the National Institutes of Health (NIH).

10 Sep 2010

UK researchers discover new tactic used by cancer cells to cheat death

Cancer Research UK scientists have uncovered a new strategy that could be used by cancer cells to side step the body's normal safety checks and become immortal a key step for a cancer cell according to a study published in Nature today (Thursday).

10 Sep 2010

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for the NimbleGen SeqCap EZ Exome workflow. They will provide target-enrichment services using NimbleGen SeqCap EZ Human Exome coupled with next-generation sequencing services for genetic research.

9 Sep 2010

Study suggests PTSD symptoms common in Second Generation population

In groups with high rates of posttraumatic stress disorder (PTSD), such as the survivors of the Nazi Death Camps, the adjustment problems of their children, the so called "Second Generation", have received attention by researchers. Studies suggested that some symptoms or personality traits associated with PTSD may be more common in the Second Generation than the general population.

9 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

Researchers unveil protection mechanism of telomeres from DNA repair

In the latest issue of the journal Nature, Miguel Godinho Ferreira, Principal Investigator at the Instituto Gulbenkian de Ciência (IGC) in Portugal, lead a team of researchers to shed light on a paradox that has puzzled biologists since the discovery of telomeres, the protective tips of chromosomes: while broken chromosome ends generated by DNA damage (such as radiation or cigarette smoke) are quickly joined together, telomeres are never tied to each other, thus allowing for the correct segregation of the genetic material into all cells in our body.

9 Sep 2010

Cellectis acquires assets of Cyto Pulse Sciences

Cellectis, the French genome engineering specialist, has announced today that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment.

9 Sep 2010

Researchers reveal surface protein alteration mechanism of mycoplasma bacteria

Pathogenic bacteria have evolved a variety of mechanisms to avoid being killed by the immune systems of the humans and animals they invade. Among the most sophisticated is that practised by mycoplasmas, which regularly change their surface proteins to confuse the immune system. Recent work in the group of Renate Rosengarten and Rohini Chopra-Dewasthaly at the University of Veterinary Medicine, Vienna has revealed surprising new details of the way they do so and at the same time raised important evolutionary questions.

9 Sep 2010

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

Helicos accuses PacBio of patent infringement, files lawsuit

Helicos BioSciences Corporation announced today that it has filed a lawsuit against Pacific Biosciences of California, Inc. for patent infringement. The lawsuit, filed in the United States District Court for the District of Delaware, accuses PacBio of infringing four patents and seeks injunctive relief and monetary damages.

9 Sep 2010

Ohio State University receives five-year grant to improve drug therapy using gene profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

9 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

DNA News and Research

Further Reading

Good Start Genetics $18 million Series A financing round co-led by Safeguard Scientifics

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

SAEC collaborates with Newcastle University for drug induced liver injury research

Research into role of genetic variation in drug-induced hypersensitivity reactions

Researchers discover mechanism that prevents stem cell from becoming another cell type

Kennedy Krieger Institute receives grant for Alzheimer's disease research in Down syndrome patients

UK researchers discover new tactic used by cancer cells to cheat death

Roche announces Ambry Genetics as first US CSP for NimbleGen SeqCap EZ Exome workflow

Study suggests PTSD symptoms common in Second Generation population

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

Two genes linked to ovarian clear cell carcinoma

Researchers unveil protection mechanism of telomeres from DNA repair

Cellectis acquires assets of Cyto Pulse Sciences

Researchers reveal surface protein alteration mechanism of mycoplasma bacteria

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Helicos accuses PacBio of patent infringement, files lawsuit

Ohio State University receives five-year grant to improve drug therapy using gene profiles

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Understanding the DNA Damage Response in Innate Immunity eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo